Recombinant human erythropoietin (rh-Epo) administration to normal child bone marrow donors.

abstract：:In the United States the increasing number of Food and Drug Administration (FDA)-approved, innovative, and potentially effective commercial cancer therapies pose a significant financial burden on public and private payers. Chimeric antigen receptor (CAR) T cells are prototypical of this challenge. In 2017 and 2018, ti...

journal_title：Bone marrow transplantation

authors： Fiorenza S,Ritchie DS,Ramsey SD,Turtle CJ,Roth JA

更新日期：2020-09-01 00:00:00

abstract：:The preimmune status of the early gestational age fetus provides a permissive environment that bypasses the immunological barrier and permits the engraftment and expression of hemopoietic stem cells (HSC). We used in utero approach to establish long term (greater than 2 years) engraftment and expression of human fetal...

journal_title：Bone marrow transplantation

authors： Zanjani ED,Pallavacini MG,Ascensao JL,Flake AW,Harrison MR,Tavassoli M

更新日期：1992-01-01 00:00:00

abstract：:The efficacy of ciprofloxacin as antibacterial prophylaxis for allogeneic bone marrow transplantation has been well documented, and it virtually eliminated bacteremias caused by gram-negative pathogens in early reports. Ciprofloxacin was therefore incorporated into the prophylactic antibiotic regimen during allogeneic...

journal_title：Bone marrow transplantation

authors： Yeh SP,Hsueh EJ,Yu MS,Wu H,Wang YC

更新日期：1999-12-01 00:00:00

abstract：:We analyzed late cardiovascular outcomes of 661 patients who survived at least 2 years from hematopoietic cell transplantation for childhood hematologic malignancy between 1995 and 2008. Center for International Blood and Marrow Transplant Research data was supplemented with surveys focused on cardiotoxicity and poten...

journal_title：Bone marrow transplantation

authors： Duncan CN,Brazauskas R,Huang J,Shaw BE,Majhail NS,Savani BN,Flowers MED,Battiwalla M,Beebe K,Dietz AC,Dvorak CC,Giller R,Jacobsohn DA,Kletzel M,Martin PL,Nemecek ER,Nuechterlein B,Talano JA,Pulsipher MA,Baker KS

更新日期：2018-10-01 00:00:00

abstract：:The administration of G-CSF post transplant has been shown to accelerate the time to neutrophil engraftment. However, this does not necessarily translate into a meaningful clinical benefit to the patient. This randomized study was designed to determine the role of G-CSF following transplantation in patients with breas...

journal_title：Bone marrow transplantation

authors： Hornedo J,Solá C,Solano C,López JJ,Alonso S,Lluch A,Ojeda B,Garcia-Conde J,Cortés-Funes H,SOLTI Group.

更新日期：2002-05-01 00:00:00

abstract：:Large registry studies have shown superior disease-free survival (DFS) with matched sibling donor (MSD) allogeneic hematopoietic cell transplantation (allo-HCT) over chemotherapy alone for patients with B-precursor acute lymphoblastic leukemia (ALL) and a late BM relapse. As most of these patients will not have an MSD...

journal_title：Bone marrow transplantation

authors： Beck JC,Cao Q,Trotz B,Smith AR,Weigel BJ,Verneris MR,Burke MJ

更新日期：2011-07-01 00:00:00

abstract：:On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic ...

journal_title：Bone marrow transplantation

authors： Kansagra AJ,Frey NV,Bar M,Laetsch TW,Carpenter PA,Savani BN,Heslop HE,Bollard CM,Komanduri KV,Gastineau DA,Chabannon C,Perales MA,Hudecek M,Aljurf M,Andritsos L,Barrett JA,Bachanova V,Bonini C,Ghobadi A,Gill SI,Hi

更新日期：2019-11-01 00:00:00

abstract：:Twenty-five patients with hematologic malignancies (n = 21) or aplastic anemia (n = 4) undergoing an allogeneic BMT from an HLA-identical sibling developed cytomegalovirus (CMV) antigenemia at a mean interval from BMT of 41 days (range 16-141 days). All patients were treated at the time of antigenemia in the absence o...

journal_title：Bone marrow transplantation

authors： Bacigalupo A,van Lint MT,Tedone E,Moro F,Sanna MA,Longren M,Trespi G,Frassoni F,Occhini D,Gualandi F

更新日期：1994-06-01 00:00:00

abstract：:In the current study, we evaluated a combination of tacrolimus and mycophenolate mofetil (MMF) as GvHD prophylaxis in 50 patients undergoing truly nonmyeloablative (NM; 90 mg/m(2) fludarabine, 2 Gy TBI) hematopoietic SCT (HSCT) from unrelated donors. Median patient age was 51 years (range, 25-67 years). After a median...

journal_title：Bone marrow transplantation

authors： Zohren F,Schroeder T,Czibere A,Fenk R,Bruns I,Kondakci M,Saure C,Haas R,Kobbe G

更新日期：2011-05-01 00:00:00

abstract：:In order to detect chimerism after allogeneic hematopoietic SCT (HSCT), several methods have been developed. In this study we describe the use of a set of insertion/deletion (Indel) polymorphic loci to determine the level of donor cell engraftment. We analyzed 50 DNA samples from patients who had undergone HSCT, and a...

journal_title：Bone marrow transplantation

authors： Santurtún A,Riancho JA,Yañez L,Santurtún M,Zarrabeitia MT

更新日期：2014-11-01 00:00:00

abstract：:Patterns of C-reactive protein (CRP) release were derived from frequent CRP measurements in a cohort of 66 consecutive patients receiving allogeneic bone marrow transplants (BMT) in our unit. Based on a retrospective study of clinical events occurring within the first 40 days after BMT, patients with major transplant-...

journal_title：Bone marrow transplantation

authors： Schots R,Kaufman L,Van Riet I,Lacor P,Trullemans F,De Waele M,Van Camp B

更新日期：1998-07-01 00:00:00

abstract：:Driven by access to better drugs, on average, newly diagnosed multiple myeloma patients have over 10 years overall survival. Using modern combination therapies-with or without the addition of high-dose melphalan and autologous stem cell transplantation-up to 80% of patients reach a complete response. As a logical and ...

journal_title：Bone marrow transplantation

authors： Landgren O,Devlin S,Boulad M,Mailankody S

更新日期：2016-12-01 00:00:00

abstract：:Allogeneic transplantation may be curative in a proportion of patients with multiple myeloma (MM), but relapse is a major cause of treatment failure. We sought to improve complete remission (CR) rates by the use of alpha-interferon (alpha-IFN) in patients not in CR when evaluated 4 months post-transplant. We report fi...

journal_title：Bone marrow transplantation

authors： Byrne JL,Carter GI,Bienz N,Haynes AP,Russell NH

更新日期：1998-10-01 00:00:00

abstract：:Hematopoietic SCT (HSCT) is an integral part of the management of patients with hematologic disorders. The Sultanate of Oman, with a population of 2.3 million, has an HSCT program based in the Sultan Qaboos University (SQU) hospital. Initiated in 1995, this two-bed unit continues to be the only program in the country....

journal_title：Bone marrow transplantation

authors： Dennison D,Al Kindi S,Pathare A,Daar S,Nusrat N,Ur Rehman J,Zia F,Khan H,Khan MI,Alghazaly A,Al Zadjali S,Tauro M,Al Lawatia A,Ganguly S

更新日期：2008-08-01 00:00:00

abstract：:To determine the effect of growth factor mobilization on the expression of adhesion molecules, we compared CD34+ progenitor cell (PC) populations from steady-state bone marrow (BM) with granulocyte-macrophage colony-stimulating factor (GM-CSF)-mobilized apheresis products (peripheral blood stem cell (PSC)) using flow ...

journal_title：Bone marrow transplantation

authors： Watanabe T,Dave B,Heimann DG,Lethaby E,Kessinger A,Talmadge JE

更新日期：1997-06-01 00:00:00

abstract：:The Japan Marrow Donor Program (JMDP), established in 1991, has continued to grow in its capacity to facilitate unrelated bone marrow (BMT) and peripheral blood stem cell transplantation (PBSCT) for the past 25 years in Japan. The current donor pool is 463,465 (as of 31 December 2016) and 20,237 transplants were perfo...

journal_title：Bone marrow transplantation

authors： Saito H,Ito M,Kato S,Kodera Y,Okamoto S,Taniguchi S,Takanashi M,Kanamori H,Masaoka T,Takaku F,JMDP.

更新日期：2018-05-01 00:00:00

abstract：:Although allogeneic hematopoietic stem cell transplantation (HSCT) features severe physical and psychological strain, no previous study has prospectively investigated fatigue beyond 3 years after transplantation. We investigated the temporal course of fatigue over 5 years, compared patients with the general population...

journal_title：Bone marrow transplantation

authors： Esser P,Kuba K,Mehnert A,Schwinn A,Schirmer L,Schulz-Kindermann F,Kruse M,Koch U,Zander AR,Kröger N,Schilling G,Götze H,Scherwath A

更新日期：2017-05-01 00:00:00

abstract：:To examine the effect of granulocyte colony-stimulating factor (G-CSF) on hematopoietic recovery after high-dose chemotherapy and peripheral blood progenitor cell transplantation (PBPCT), 20 patients with hematologic malignancies were divided into two groups. One group was given G-CSF at a daily dose of 50 micrograms/...

journal_title：Bone marrow transplantation

authors： Shimazaki C,Oku N,Uchiyama H,Yamagata N,Tatsumi T,Hirata T,Ashihara E,Okawa K,Goto H,Inaba T

更新日期：1994-03-01 00:00:00

abstract：:Paecilomyces varioti, a fungus resembling penicillium spp, has been described in conjunction with impaired host defence or foreign body implants. We report a case of Paecilomyces varioti catheter-related fungemia that occurred during neutropenia in an allogeneic BMT patient receiving antifungal prophylaxis with flucon...

journal_title：Bone marrow transplantation

authors： Shing MM,Ip M,Li CK,Chik KW,Yuen PM

更新日期：1996-02-01 00:00:00

abstract：:We report two children who presented with cough and shortness of breath 7-8 months after a matched sibling stem cell transplant (SCT) for chronic myelogenous leukemia and myelodysplastic syndrome, respectively. Pulmonary function tests (PFTs) revealed severe airways obstruction (AO). However, radiographic investigatio...

journal_title：Bone marrow transplantation

authors： Benesch M,Kerbl R,Schwinger W,Lackner H,Pfleger A,Popper H,Urban C

更新日期：1998-10-01 00:00:00

abstract：:Haploidentical bone marrow transplantation (BMT) is associated with a high risk of severe graft-versus-host disease (GVHD). While pan-T cell depletion of the graft is the most effective means of preventing severe GVHD, it is associated with delayed recovery of T cell function leading to fatal infections. We used two r...

journal_title：Bone marrow transplantation

authors： Mavroudis DA,Jiang YZ,Hensel N,Lewalle P,Couriel D,Kreitman RJ,Pastan I,Barrett AJ

更新日期：1996-05-01 00:00:00

abstract：:Three patients developed abdominal pain and abnormal liver enzymes without hyperbilirubinemia, early after autografting for lymphoma. Two had received conditioning therapy with busulfan, cyclophosphamide and continuous infusion etoposide; the other had received busulfan and melphalan. Doppler ultrasound in all cases d...

journal_title：Bone marrow transplantation

authors： Grigg A,Gibson R,Bardy P,Szer J

更新日期：1996-11-01 00:00:00

abstract：:Malignant infantile osteopetrosis (MIOP) is a rare hereditary disorder of osteoclast function, which can be reversed by hematopoietic stem cell transplantation (SCT). We observed a high incidence of hepatic veno-occlusive disease (VOD) in transplanted patients and explored the prevention of this complication by using ...

journal_title：Bone marrow transplantation

authors： Corbacioglu S,Hönig M,Lahr G,Stöhr S,Berry G,Friedrich W,Schulz AS

更新日期：2006-10-01 00:00:00

abstract：:An in vitro skin explant model for graft-versus-host disease (GVHD) in humans has been used to study the role of effector T cells in the histological pathogenesis of GVHD. In 11 of 12 experiments clear GVHD changes of grades II-IV were induced in HLA-mismatched skin explants cultured with allogeneic T cells sensitized...

journal_title：Bone marrow transplantation

authors： Dickinson AM,Sviland L,Carey P,Reid MM,Hamilton PJ,Pearson AJ,Proctor SJ

更新日期：1988-07-01 00:00:00

abstract：:The First International Symposium on Photopheresis in Hematopoietic Stem Cell Transplantation was held in Vienna, Austria with an educational grant from Therakos Inc. from 25 May to 27 May 2005. Three general issues were addressed: (1) pathophysiology of graft-versus-host disease (GvHD), (2) induction of immune tolera...

journal_title：Bone marrow transplantation

authors： Greinix HT,Socié G,Bacigalupo A,Holler E,Edinger MG,Apperley JF,Schwarz T,Ullrich SE,Albert ML,Knobler RM,Peritt D,Ferrara JL

更新日期：2006-08-01 00:00:00

abstract：:The purpose of the study was to evaluate the effect of lisofylline (LSF) on engraftment, regimen-related toxicities (RRT), and mortality in patients undergoing allogeneic bone marrow transplantation (BMT). We performed a multicenter, randomized placebo-controlled trial in 60 patients with hematologic malignancies rece...

journal_title：Bone marrow transplantation

authors： List AF,Maziarz R,Stiff P,Jansen J,Liesveld J,Andrews F,Schuster M,Wolff S,Litzow M,Karanes C,Dahlberg S,Kirkhart B,Bianco JA,Singer JW

更新日期：2000-02-01 00:00:00

abstract：:We report the results of a retrospective single-center study comparing engraftment, acute and chronic GVHD, relapse and survival in patients with malignant hematological disorders transplanted with allogeneic peripheral blood stem cells (alloPBSCT, n = 40) or bone marrow cells (alloBMT, n = 42). All transplants were T...

journal_title：Bone marrow transplantation

authors： Barge RM,Brouwer RE,Beersma MF,Starrenburg CW,Zwinderman AH,Hale G,Waldmann H,den Ottolander GJ,Falkenburg JH,Willemze R,Fibbe WE

更新日期：2001-05-01 00:00:00

abstract：:In this retrospective study, we evaluated the predictability of PBSC dose for hematopoietic engraftment comparing that calculated by ideal body weight (IBW) vs another calculated by actual body weight (ABW) for each patient. Sixty-three consecutive patients treated similarly using one transplant protocol were analyzed...

journal_title：Bone marrow transplantation

authors： Waples JM,Moreb JS,Sugrue M,Belanger G,Kubilis P,Lynch JW,Gian V,Weeks F,Wingard J

更新日期：1999-05-01 00:00:00

abstract：:We report long-term outcomes of 329 childhood severe aplastic anemia (SAA) patients who underwent hematopoietic SCT (HSCT) from an HLA-matched sibling donor in the Japanese Hematopoietic Cell Transplantation Registry. OS and EFS at 10 years were as high as 89.7+/-1.7% and 85.5+/-2.0%, respectively. Five cases of late ...

journal_title：Bone marrow transplantation

authors： Kikuchi A,Yabe H,Kato K,Koh K,Inagaki J,Sasahara Y,Suzuki R,Yoshida N,Kudo K,Kobayashi R,Tabuchi K,Kawa K,Kojima S

更新日期：2013-05-01 00:00:00

abstract：:Attenuated live virus vaccinations are generally recommended 24 months following hematopoietic cell transplantation (HCT) in patients not receiving immunosuppressive therapy. To date, there are no data regarding the safety of live-attenuated herpes zoster or measles-mumps-rubella (MMR) vaccinations in multiple myeloma...

journal_title：Bone marrow transplantation

authors： Pandit A,Leblebjian H,Hammond SP,Laubach JP,Richardson PG,Baden LR,Marty FM,Issa NC

更新日期：2018-07-01 00:00:00